Inhibition of glutamine metabolism has been confirmed to be promising in glutamine-addicted cancer cells, including glutamine analogs like DON, acivicin, and azaserine, glutamine transporter inhibitor GPNA and V-9302, GLS1/2 inhibitors (Shen et al., 2021). Here, GLS is linked to cancer.